HighTide Biopharma Pty Ltd. (Australia)

HighTide Biopharma Pty Ltd. (Australia) is the Australian subsidiary of HighTide Therapeutics, Inc., a clinical-stage biopharmaceutical company founded in 2011 by Dr. Liping Liu. The parent company, listed on the Hong Kong Stock Exchange under the ticker 2511.HK, is dedicated to discovering and developing multifunctional, multi-targeted therapies for cardiovascular-kidney-metabolic (CKM) diseases. The Australian entity, based in Sydney, forms part of HighTide's globally integrated research and development network. HighTide's lead asset, HTD1801, is a first-in-class oral small molecule with a dual mechanism of action targeting insulin resistance and chronic inflammation. It is being developed for a range of CKM indications including type 2 diabetes mellitus (T2DM), metabolic dysfunction-associated steatohepatitis (MASH), obesity, primary sclerosing cholangitis (PSC), and chronic kidney disease (CKD). HTD1801 has received two Fast Track designations and one Orphan Drug designation from the US Food and Drug Administration, and has been selected for China's National Major Science and Technology Project for Significant New Drug Development. The company's pipeline extends beyond HTD1801 with a growing discovery portfolio focused on the interconnections between cardiovascular, renal, and metabolic conditions. HighTide's research has been presented at major academic conferences including those of the American Society of Nephrology (ASN), European Renal Association (ERA), European Society of Cardiology (ESC), American Association for the Study of Liver Diseases (AASLD), European Association for the Study of the Liver (EASL), American Diabetes Association (ADA), and European Association for the Study of Diabetes (EASD), and published in journals such as Nature, JAMA, and NEJM. As an Australian subsidiary, HighTide Biopharma Pty Ltd. contributes to the group's global clinical development and research activities. The parent company maintains a presence in multiple markets including China, the United States, and Australia, reflecting its strategy of globally integrated drug development. HighTide Therapeutics is recognized as a National High-Tech Enterprise of China and an Innovative Small and Medium-sized Enterprise (SME), and was among the first batch of Strategic Enterprise Partners of the Hong Kong SAR Government.

HighTide Therapeutics, Inc. was founded in 2011 by Dr. Liping Liu, a scientist with over 20 years of R&D leadership experience and more than 100 patents and patent applications. Prior to founding HighTide, Dr. Liu held leadership positions at CTL ImmunoTherapies Corporation, MannKind Corporation, Stealth Peptide Inc., and ABLE BioGroup LLC. She received her bachelor's degree in chemistry and doctoral degree in physics of polymer from Nankai University, completed post-doctoral training at the University of Toronto, and obtained an MBA from the Johns Hopkins University Carey Business School. The company was established with a focus on developing novel therapies for metabolic and digestive diseases, an area where Dr. Liu is recognized as a pioneer. Over the years, HighTide built an innovative, globally integrated pipeline of proprietary assets and advanced multiple clinical programs across cardiovascular-kidney-metabolic (CKM) diseases. The company's lead asset, HTD1801, is a first-in-class oral small molecule with a dual mechanism of action targeting insulin resistance and chronic inflammation. It has received two Fast Track designations and one Orphan Drug designation from the US Food and Drug Administration (FDA), and has been selected for China's National Major Science and Technology Project for Significant New Drug Development. HTD1801 is being developed for multiple indications including type 2 diabetes mellitus (T2DM), metabolic dysfunction-associated steatohepatitis (MASH), obesity, primary sclerosing cholangitis (PSC), and chronic kidney disease (CKD). HighTide Therapeutics is listed on the Hong Kong Stock Exchange under the ticker 2511.HK. The company has been recognized as a National High-Tech Enterprise of China and an Innovative Small and Medium-sized Enterprise (SME), and was among the first batch of Strategic Enterprise Partners of the Hong Kong SAR Government. Its research findings have been presented at top-tier academic conferences including the American Society of Nephrology (ASN), European Renal Association (ERA), Global Cardiovascular Clinical Trialists Forum (CVCT), European Society of Cardiology (ESC), American Association for the Study of Liver Diseases (AASLD), European Association for the Study of the Liver (EASL), American Diabetes Association (ADA), and European Association for the Study of Diabetes (EASD), and published in prestigious journals such as Nature, JAMA, and NEJM. HighTide Biopharma Pty Ltd. (Australia) is the Australian subsidiary of HighTide Therapeutics, Inc., based in Sydney. It forms part of the group's global R&D and clinical development network, contributing to the company's mission of delivering breakthrough treatments that generate comprehensive, multi-organ benefits for patients worldwide.

• 2011

  HighTide Therapeutics, Inc. founded by Dr. Liping Liu.

• HTD1801 receives two Fast Track designations and one Orphan Drug designation from the US FDA.

• HTD1801 selected for China's National Major Science and Technology Project for Significant New Drug Development.

• HighTide Therapeutics listed on the Hong Kong Stock Exchange (ticker: 2511.HK).

• HighTide Biopharma Pty Ltd. (Australia) established as subsidiary in Sydney.

Clinical-stage biopharmaceutical company focused on innovative multifunctional therapies for cardiovascular-kidney-metabolic (CKM) diseases.

• HTD1801

  First-in-class oral small molecule with dual mechanism of action targeting insulin resistance and chronic inflammation; being developed for T2DM, MASH, obesity, PSC, and CKD.

1. 1Home - HighTide Therapeutics, Inc.hightidetx.com
2. 2Company Overview - HighTide Therapeutics, Inc.hightidetx.com
3. 3Contact - HighTide Therapeutics, Inc.hightidetx.com
4. 4Leadership - HighTide Therapeutics, Inc.hightidetx.com
5. 5HighTide Biopharma Pty Ltd. (Australia) - Wikidatawikidata.org